UA80957C2 - Method of administering a thymosin alpha 1 peptide - Google Patents

Method of administering a thymosin alpha 1 peptide Download PDF

Info

Publication number: UA80957C2
Authority: UA; Ukraine
Prior art keywords: specified; peptide; patient; indicated; thymosin
Prior art date: 2001-11-01

Application number

UA20040504064A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-01

Filing date

2002-01-11

Publication date

2007-11-26

2002-01-11 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2007-11-26 Publication of UA80957C2 publication Critical patent/UA80957C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 27
108010078233 Thymalfasin Proteins 0.000 title abstract 4
238000001802 infusion Methods 0.000 claims abstract description 34
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 30
230000004936 stimulating effect Effects 0.000 claims abstract 2
238000011282 treatment Methods 0.000 claims description 41
108010046075 Thymosin Proteins 0.000 claims description 13
230000000694 effects Effects 0.000 claims description 12
230000003308 immunostimulating effect Effects 0.000 claims description 11
210000004698 lymphocyte Anatomy 0.000 claims description 11
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 11
102000004127 Cytokines Human genes 0.000 claims description 10
108090000695 Cytokines Proteins 0.000 claims description 10
102000007501 Thymosin Human genes 0.000 claims description 10
210000000265 leukocyte Anatomy 0.000 claims description 9
210000003714 granulocyte Anatomy 0.000 claims description 8
238000010254 subcutaneous injection Methods 0.000 claims description 6
239000007929 subcutaneous injection Substances 0.000 claims description 6
230000037396 body weight Effects 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 2
230000003204 osmotic effect Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
210000000987 immune system Anatomy 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000000638 stimulation Effects 0.000 abstract description 6
102400000800 Thymosin alpha-1 Human genes 0.000 abstract 2
NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 2
229960004231 thymalfasin Drugs 0.000 abstract 2
241001465754 Metazoa Species 0.000 description 16
210000004027 cell Anatomy 0.000 description 15
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
241000700159 Rattus Species 0.000 description 6
238000000684 flow cytometry Methods 0.000 description 6
238000011084 recovery Methods 0.000 description 6
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 4
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
229960002949 fluorouracil Drugs 0.000 description 3
208000005176 Hepatitis C Diseases 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
MFRCZYUUKMFJQJ-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1COC(=O)CO1 MFRCZYUUKMFJQJ-UHFFFAOYSA-N 0.000 description 1
101100289989 Drosophila melanogaster alpha-Man-Ia gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
101150021286 MAS1 gene Proteins 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
238000011342 chemoimmunotherapy Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
NBNNDUZYMXBCOX-UHFFFAOYSA-N n-[4-[4-(4-methoxyphenoxy)-2,6-dimethylphenyl]-1,3-thiazol-2-yl]pyridine-4-carboxamide Chemical compound C1=CC(OC)=CC=C1OC(C=C1C)=CC(C)=C1C1=CSC(NC(=O)C=2C=CN=CC=2)=N1 NBNNDUZYMXBCOX-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
108700016958 thymosin fraction 5 Proteins 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Oncology (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

UA20040504064A 2001-11-01 2002-01-11 Method of administering a thymosin alpha 1 peptide UA80957C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33087401P	2001-11-01	2001-11-01
PCT/US2002/035093 WO2003037366A1 (en)	2001-11-01	2002-11-01	Method of administering a thymosin alpha 1 peptide

Publications (1)

Publication Number	Publication Date
UA80957C2 true UA80957C2 (en)	2007-11-26

Family

ID=23291672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040504064A UA80957C2 (en)	2001-11-01	2002-01-11	Method of administering a thymosin alpha 1 peptide

Country Status (19)

Country	Link
US (2)	US20050049191A1 (de)
EP (1)	EP1450850B1 (de)
JP (1)	JP2005511563A (de)
KR (1)	KR20050042229A (de)
CN (1)	CN1582163A (de)
AT (1)	ATE481980T1 (de)
AU (1)	AU2002363248B2 (de)
BR (1)	BR0213823A (de)
CA (1)	CA2464307A1 (de)
DE (1)	DE60237784D1 (de)
EA (1)	EA008536B1 (de)
ES (1)	ES2353379T3 (de)
IL (2)	IL161665A0 (de)
MX (1)	MXPA04004187A (de)
NO (1)	NO327101B1 (de)
NZ (1)	NZ532763A (de)
PL (1)	PL208388B1 (de)
UA (1)	UA80957C2 (de)
WO (1)	WO2003037366A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7897567B2 (en) *	2002-11-25	2011-03-01	Sciclone Pharmaceuticals, Inc.	Methods of protecting against radiation damage using alpha thymosin
DK1613340T3 (da) *	2003-03-28	2010-08-30	Sciclone Pharmaceuticals Inc	Behandling af aspergillus-infektioner med thymosin alfa 1
US8017129B2 (en) *	2006-06-15	2011-09-13	SciClone Pharmaceuticals International Ltd	Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) *	2007-06-01	2008-12-04	Sciclone Pharmaceuticals, Inc.	Treatment of Melanoma with Alpha Thymosin Peptides
AU2008338594A1 (en) *	2007-12-14	2009-06-25	Sciclone Pharmaceuticals, Inc.	Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
WO2010129947A2 (en)	2009-05-08	2010-11-11	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers
HK1207008A1 (en) *	2012-03-08	2016-01-22	Sciclone Pharmaceuticals, Inc.	Use of thymosin alpha for treatment of purulent rhinosinusitis
US20130296223A1 (en)	2012-03-30	2013-11-07	Sciclone Pharmaceuticals, Inc.	Use of thymosin alpha for the treatment of sepsis
JP6821560B2 (ja) *	2014-10-21	2021-01-27	サイクロンファーマシューティカルズインターナショナルエルティーディー．ＳｃｉｃｌｏｎｅＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｔｅｒｎａｔｉｏｎａｌＬｔｄ．	免疫刺激剤による癌治療
AU2016217473B2 (en) *	2015-02-09	2021-07-29	Sciclone Pharmaceuticals International (Sg) Pte. Ltd.	Thymosin alpha 1 for use in treatment of cystic fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4447233A (en) *	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4444757A (en) *	1981-11-16	1984-04-24	Research Corporation	Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (de) *	1991-09-13	1994-05-21	Paul B Chretien
US5468729A (en) *	1993-10-26	1995-11-21	Alpha 1 Biomedicals	Method for treatment of autoimmune hepatitis
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5888980A (en) *	1994-06-30	1999-03-30	Bio-Logic Research And Development Corporation	Compositions for enhancing immune function
US5632983A (en) *	1994-11-17	1997-05-27	University Of South Florida	Method for treating secondary immunodeficiency
US5849596A (en) *	1996-07-08	1998-12-15	Food Industry Research And Development Institute	Process for determining the smoke content of edible oil
AU7788701A (en) *	2000-07-14	2002-01-30	Transform Pharmaceuticals Inc	System and method for optimizing tissue barrier transfer of compounds
EP1343528A2 (de) *	2000-11-02	2003-09-17	Research Foundation of City University of New York	Methoden zur stimulierung der regeneration und reparatur des nervensystems durch hemmung der phosphodiesterase typ 4

2002
- 2002-01-11 UA UA20040504064A patent/UA80957C2/uk unknown
- 2002-11-01 WO PCT/US2002/035093 patent/WO2003037366A1/en not_active Ceased
- 2002-11-01 ES ES02802520T patent/ES2353379T3/es not_active Expired - Lifetime
- 2002-11-01 AU AU2002363248A patent/AU2002363248B2/en not_active Ceased
- 2002-11-01 NZ NZ532763A patent/NZ532763A/en not_active IP Right Cessation
- 2002-11-01 JP JP2003539708A patent/JP2005511563A/ja active Pending
- 2002-11-01 US US10/493,848 patent/US20050049191A1/en not_active Abandoned
- 2002-11-01 AT AT02802520T patent/ATE481980T1/de not_active IP Right Cessation
- 2002-11-01 CN CNA02821871XA patent/CN1582163A/zh active Pending
- 2002-11-01 DE DE60237784T patent/DE60237784D1/de not_active Expired - Lifetime
- 2002-11-01 BR BR0213823-9A patent/BR0213823A/pt not_active IP Right Cessation
- 2002-11-01 EA EA200400591A patent/EA008536B1/ru not_active IP Right Cessation
- 2002-11-01 EP EP02802520A patent/EP1450850B1/de not_active Expired - Lifetime
- 2002-11-01 IL IL16166502A patent/IL161665A0/xx active IP Right Grant
- 2002-11-01 KR KR1020047006674A patent/KR20050042229A/ko not_active Ceased
- 2002-11-01 PL PL370430A patent/PL208388B1/pl not_active IP Right Cessation
- 2002-11-01 CA CA002464307A patent/CA2464307A1/en not_active Abandoned
- 2002-11-01 MX MXPA04004187A patent/MXPA04004187A/es active IP Right Grant
2004
- 2004-04-29 IL IL161665A patent/IL161665A/en not_active IP Right Cessation
- 2004-05-21 NO NO20042100A patent/NO327101B1/no not_active IP Right Cessation
2010
- 2010-05-07 US US12/775,986 patent/US20100221274A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1450850B1 (de)	2010-09-22
AU2002363248B2 (en)	2007-11-22
DE60237784D1 (de)	2010-11-04
EP1450850A1 (de)	2004-09-01
IL161665A0 (en)	2004-09-27
PL370430A1 (en)	2005-05-30
EA200400591A1 (ru)	2004-10-28
ATE481980T1 (de)	2010-10-15
PL208388B1 (pl)	2011-04-29
CA2464307A1 (en)	2003-05-08
ES2353379T3 (es)	2011-03-01
EA008536B1 (ru)	2007-06-29
CN1582163A (zh)	2005-02-16
BR0213823A (pt)	2004-08-31
MXPA04004187A (es)	2004-07-08
NO20042100D0 (no)	2004-05-21
EP1450850A4 (de)	2005-11-30
WO2003037366A1 (en)	2003-05-08
IL161665A (en)	2011-03-31
US20100221274A1 (en)	2010-09-02
NO20042100L (no)	2004-05-21
KR20050042229A (ko)	2005-05-06
US20050049191A1 (en)	2005-03-03
NZ532763A (en)	2008-01-31
NO327101B1 (no)	2009-04-20
JP2005511563A (ja)	2005-04-28

Publication	Publication Date	Title
US20100221274A1 (en)	2010-09-02	Method of administering a thymosin alpha 1 peptide
Cárdenas-Camarena et al.	1999	Combined gluteoplasty: liposuction and lipoinjection
JP4416839B2 (ja)	2010-02-17	二次性免疫不全症の治療法
AU698410B2 (en)	1998-10-29	Use of interleukin-12 to prevent graft versus host disease
Sayers et al.	1990	Antitumor effects of α-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo
US20080152668A1 (en)	2008-06-26	Thymosin Alpha 1 Peptide/Polymer Conjugates
JP2009001590A (ja)	2009-01-08	短期及び長期の薬剤薬量決定のための方法
RU2313364C2 (ru)	2007-12-27	Способы индукции длительного иммунного ответа
AU2008335840A1 (en)	2009-06-18	Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
AU2002363248A1 (en)	2003-07-10	Method of administering a Thymosin alpha 1 peptide
AU2002353964A1 (en)	2003-07-10	Thymosin alpha 1 peptide/polymer conjugates
Marshall et al.	1997	Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide
Zeuzem	2006	The American Association for the Study of Liver Diseases: new perspectives in the treatment of hepatitis C
MXPA05011304A (es)	2005-12-12	Composiciones a base de peptidos de alfa timosina para el tratamiento y prevencion de infecciones virales respiratorias.
AU2008200190A1 (en)	2008-02-07	Method of Administering a Thymosin Alpha 1 Peptide
Beniers et al.	1990	In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system
Hirashima et al.	1993	Induction of an eosinophil chemotactic factor production from T lymphocytes by a B cell lymphoma line
JP2009091348A (ja)	2009-04-30	がんの治療方法
Ohnishi et al.	1993	Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery
van Dijk	2018	Delivery of biologicals: Sustained release of cell-specific proteins in fibrosis
Schiiller et al.	1992	Pharmacokinetic Aspects of Interferon Alfa-2b After Intrahepatic or Intraperitoneal Administration